Objective: This study evaluated the QoL of Brazilian adult patients with childhood-onset growth hormone deficiency GHD (CO-GHD), comparing those who continued GH replacement therapy (GHRT) after transition to adulthood with those who discontinued treatment and with healthy subjects. Subjects and methods: In this cross-sectional study, quality of life (QoL) was assessed using the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) questionnaire in 61 Brazilian adults aged 18-50 years. The sample included 31 patients with CO-GHD confirmed during the transition period, who continued or discontinued GHRT, and 30 matched controls. Results: GHD patients had poorer QoL, as indicated by higher QoLAGHDA scores than controls (median 8 [IQR 5-14] vs 4 [IQR 2-8]; p < 0.01). Continued GHRT in adulthood did not impact QoL compared with discontinued GHRT (8 [IQR 6-16] vs. 9 [IQR 5-12], p = 0.33). Overall, women had lower QoL irrespective of GHD (9 [IQR 6-13] vs. 5 [IQR 2-8.5], p = 0.01, women and men, respectively). We found no association between QoL-AGHDA scores and education level (p = 0.51), short stature (p = 0.78), associated pituitary deficiencies (p = 0.34), or overweight/obesity (p = 0.16). Conclusion: GHD impairs quality of life in young adults; however, our cross-sectional cohort did not show significant improvements in quality of life associated with GH replacement therapy. A multidisciplinary approach combining individualized treatment and psychosocial interventions remains essential.